IMDC

International mRCC Database Consortium #IMDC #kcsm

[Ziad Bakouny, MD, MSc @ZiadBakouny]

Post-call in the CCU, so late in sharing this but thrilled to see our work on upfront cytoreductive nephrectomy in metastatic RCC now published in @EUplatinum

Huge thanks to co-first author @TalalZarif1 and co-senior @Wanling50578056 @DrDanielHeng @DrChoueiri & @IMDConline (1/1)

[Toni Choueiri, MD @DrChoueiri]

JUST IN: Cytoreductive Nephrectomy for Metastatic RCC Treated with Immune Checkpoint Inhibitors or Targeted Therapy: The @IMDConline does it again ! #IMDC @DrDanielHeng with @TalalZarif1 @ZiadBakouny @ShaanDudani et al in @EUplatinum

https://t.co/1DSzGz1cEJ

[Sumanta K. Pal, MD, FASCO @montypal]

Phenomenal work from @anobelodisho collaborating with @IMDConline @DrChoueiri @DrDanielHeng @gorejohn - this will be a useful tool for so many!

[Chun Loo Gan @ChunLGan]

Just out in EJC: Outcomes of pts treated with 1L IO agents who were trial ineligible. Big thanks to all patients, Alberta Immunotherapy Database @dmeyzie IgorStukalin, @IMDConline collaborators and my mentor @DrDanielHeng
@DrChoueiri @montypal @OncoAlert
https://t.co/Li5CwJWKD5

[Daniel Heng @DrDanielHeng]

Alberta Immunotherapy Database-led study shows pts that are trial ineligible by common criteria have poorer associated outcomes to 1st line IO in #kidneycancer #lungcancer #melanoma so expectations need to be tempered. @albertacancer #RWE @IMDConline Proud of @ChunLGan🇦🇺🇨🇦🇲🇾!

[IMDC @IMDConline]

Congratulations @DrJeffreyGraham!!

[European Urology Oncology @EurUrolOncol]

This month’s @EurUrolOncol #SoMe Award is presented to…

Outcomes of Patients with Metastatic RCC Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors

https://t.co/HI1T6IOvOf

Congrats to @DrJeffreyGraham, Amishi Y. Shah & coauthors!

#kidneycancer

[Sumanta K. Pal, MD, FASCO @montypal]

For my colleagues in #GeriOnc, nice article led by @DVAraujoMD & @ShaanDudani looking at age & outcome w ICIs in #kidneycancer. The @IMDConline strikes again (thx @DrDanielHeng @DrChoueiri) suggesting no diff in OS based on age; RR diff in 1L intriguing?

[Sumanta K. Pal, MD, FASCO @montypal]

Woderful work by @lalaniMD using the @IMDConline database w @DrDanielHeng @DrChoueiri et al! The IMDC is a gift that keeps on giving ... valuable clinical insights. @ZiadBakouny @ShaanDudani

[Ziad Bakouny, MD, MSc @ZiadBakouny]

Thrilled to see our paper out in @JAMAOnc!
@lalaniMD @DrChoueiri @DrDanielHeng @ShaanDudani
@FDonskov @IMDConline

The IO sequel to the original obesity paradox in mRCC!
@OncoAlert @urotoday @OncLive

[Aly-Khan Lalani @lalaniMD]

As always, thanks to important contributions by international investigators, sites, and *most importantly* patients to team efforts like @IMDConline

@montypal @DrVaishampayan @Wanling50578056 @steinharterjack @JustinFleische6 @PierVitaleNuzzo @nbasappaCCI + more! 👏👏👏

[Andrew Schmidt @dr_aschmidt]

4/ Looking at all patients with mRCC, incorporating the very favorable category into IMDC criteria, we can identify 4 distinct prognostic groups. @DrBryanChan @JeffreyCGoh1

[Yüksel Ürün @DrYukselUrun]

Outcomes of 1st line combos in inter/poor-risk mRCC from @IMDConline @ChunLGan
🔶Higher ORR, lower PD with IO-VEGF/TKI
🔶Similar oncological outcomes!
🔶Higher irAEs with nivo-ipi but may predict better outcomes!
@OncoAlert #GU21

[Andrew Schmidt @dr_aschmidt]

RCC has diverse outcomes: proud to be part of work @ASCO #GU21 from @DrChoueiri @DrDanielHeng @IMDConline where we identify a very favorable prognostic group of patients https://t.co/VOvxolsXjd

@ZiadBakouny @ShaanDudani @neerajaiims

[Toni Choueiri, MD @DrChoueiri]

Now with @ChunLGan @IMDConline with real-word evidence showing equivalent OS and TTNT between IO-IO and IO-VEGF regimens in poor/interm. risk mRCC !! @ASCO #GU21

@ASCO_pubs @ASCOPost @DrDanielHeng @montypal @TiansterZhang @ZiadBakouny @AlbigesL @urotoday @OncoAlert @DanaFarber

[Jeffrey Graham @DrJeffreyGraham]

Our @IMDConline analysis on the effectiveness of first-line ICI based therapy in advanced non-clear cell RCC!
@DrDanielHeng @DrChoueiri @montypal #GU21

[Chun Loo Gan @ChunLGan]

In this real-world study, Cabozantinib has activity across 1L-4L settings in #mRCC. Dose reduction for AEs was associated with better outcomes. Thanks to all @IMDConline collaborators!

https://t.co/BN7S4Cl6k9
@DrDanielHeng @DrChoueiri @ShaanDudani @FDonskov @DrBenTran @montypal

[Nils Kröger @KrgerMd]

@DrDanielHeng @ShaanDudani @OncoAlert @OncEd @JAMANetworkOpen @JAMAOnc Congrats @ShaanDudani and @DrDanielHeng for this important work! Thanks for including us.

[Shaan Dudani @ShaanDudani]

Just out in @JAMANetworkOpen: Sites of metastasis vary by histology in mRCC and are associated with OS. Thanks to all @IMDConline collaborators!

@DrDanielHeng @DrChoueiri @ChunLGan @g_develasco @CPRT65 @FDonskov @montypal @ravikanesvaran @NeilReaumeMD

https://t.co/UIghsiPq5T

[JAMA Network Open @JAMANetworkOpen]

Cohort study finds metastases vary between histologic subtypes of mRCC, sites of metastatic involvement are associated with survival: ccRCC = ↑ lung, brain, adrenal, pancreas mets pRCC = ↑ lymph node mets chrRCC = ↑ liver mets @ShaanDudani @DrDanielHeng https://t.co/EdEypezyLT

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Great work to see sites of metastasis with survival outcomes in @IMDConline. Good reference for oncologists who treat #kidneycancer.